JPS58113189A - 螢光偏光免疫分析 - Google Patents

螢光偏光免疫分析

Info

Publication number: JPS58113189A
Authority: JP; Japan
Prior art keywords: ligand; compound according; group; tracer; derived
Prior art date: 1981-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP57214749A

Other languages

English (en)

Japanese (ja)

Inventor

チヤオ−フエイ・ジエフリ−・ワング

ステフアン・デナム・ストロ−プ

マイケル・ア−ネスト・ジヨレイ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-12-11

Filing date

1982-12-09

Publication date

1983-07-05

1982-12-09 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

1983-07-05 Publication of JPS58113189A publication Critical patent/JPS58113189A/ja

Status Pending legal-status Critical Current

Links

230000010287 polarization Effects 0.000 title description 19
239000003446 ligand Substances 0.000 claims description 80
239000000700 radioactive tracer Substances 0.000 claims description 52
238000000034 method Methods 0.000 claims description 48
150000001875 compounds Chemical class 0.000 claims description 37
239000001961 anticonvulsive agent Substances 0.000 claims description 17
150000003839 salts Chemical class 0.000 claims description 15
238000002875 fluorescence polarization Methods 0.000 claims description 14
229960000623 carbamazepine Drugs 0.000 claims description 11
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 11
150000001412 amines Chemical class 0.000 claims description 8
239000003416 antiarrhythmic agent Substances 0.000 claims description 8
239000000935 antidepressant agent Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
150000003431 steroids Chemical group 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
229940125681 anticonvulsant agent Drugs 0.000 claims description 6
229940005513 antidepressants Drugs 0.000 claims description 6
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
229940127121 immunoconjugate Drugs 0.000 claims description 6
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 5
229940124346 antiarthritic agent Drugs 0.000 claims description 5
239000003435 antirheumatic agent Substances 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
229960002036 phenytoin Drugs 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 4
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 4
229960002393 primidone Drugs 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 3
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 3
229960004801 imipramine Drugs 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
239000013078 crystal Substances 0.000 claims description 2
238000005516 engineering process Methods 0.000 claims description 2
150000001261 hydroxy acids Chemical class 0.000 claims description 2
239000002207 metabolite Substances 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
230000001773 anti-convulsant effect Effects 0.000 claims 12
229960003965 antiepileptics Drugs 0.000 claims 11
239000005556 hormone Substances 0.000 claims 6
229940088597 hormone Drugs 0.000 claims 6
239000003242 anti bacterial agent Substances 0.000 claims 5
230000001430 anti-depressive effect Effects 0.000 claims 5
230000003177 cardiotonic effect Effects 0.000 claims 4
229930182470 glycoside Natural products 0.000 claims 4
150000002338 glycosides Chemical class 0.000 claims 4
239000000924 antiasthmatic agent Substances 0.000 claims 3
229940088710 antibiotic agent Drugs 0.000 claims 3
239000000853 adhesive Substances 0.000 claims 2
230000001070 adhesive effect Effects 0.000 claims 2
239000002246 antineoplastic agent Substances 0.000 claims 2
230000003115 biocidal effect Effects 0.000 claims 2
229940124530 sulfonamide Drugs 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 1
230000003288 anthiarrhythmic effect Effects 0.000 claims 1
230000002456 anti-arthritic effect Effects 0.000 claims 1
230000001088 anti-asthma Effects 0.000 claims 1
229940124599 anti-inflammatory drug Drugs 0.000 claims 1
239000000164 antipsychotic agent Substances 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
239000000496 cardiotonic agent Substances 0.000 claims 1
229940125810 compound 20 Drugs 0.000 claims 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 claims 1
125000000565 sulfonamide group Chemical group 0.000 claims 1
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
239000000203 mixture Substances 0.000 description 27
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 23
239000000243 solution Substances 0.000 description 16
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000000872 buffer Substances 0.000 description 9
229960002695 phenobarbital Drugs 0.000 description 9
-1 phlogesterone Chemical compound 0.000 description 9
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 8
230000027455 binding Effects 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 8
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
229960004194 lidocaine Drugs 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000012043 crude product Substances 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000003292 glue Substances 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
229960005091 chloramphenicol Drugs 0.000 description 4
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
239000012530 fluid Substances 0.000 description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
229960005156 digoxin Drugs 0.000 description 3
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 3
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000010791 quenching Methods 0.000 description 3
150000003873 salicylate salts Chemical class 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
229960000278 theophylline Drugs 0.000 description 3
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
239000004020 conductor Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
108010074605 gamma-Globulins Proteins 0.000 description 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
229960000240 hydrocodone Drugs 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000001841 imino group Chemical group [H]N=* 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
229960001404 quinidine Drugs 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
229940034208 thyroxine Drugs 0.000 description 2
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 description 1
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
229960001091 chenodeoxycholic acid Drugs 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
238000007667 floating Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000423 heterosexual effect Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000001465 metallisation Methods 0.000 description 1
ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000003431 oxalo group Chemical group 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229960002808 pholcodine Drugs 0.000 description 1
GPFAJKDEDBRFOS-FKQDBXSBSA-N pholcodine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCCN1CCOCC1 GPFAJKDEDBRFOS-FKQDBXSBSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical class NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP57214749A 1981-12-11 1982-12-09 螢光偏光免疫分析 Pending JPS58113189A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32997581A	1981-12-11	1981-12-11
US329975		1981-12-11

Publications (1)

Publication Number	Publication Date
JPS58113189A true JPS58113189A (ja)	1983-07-05

Family

ID=23287816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57214749A Pending JPS58113189A (ja)	1981-12-11	1982-12-09	螢光偏光免疫分析

Country Status (9)

Country	Link
JP (1)	JPS58113189A (it)
AU (1)	AU558800B2 (it)
BE (1)	BE895300A (it)
CA (1)	CA1248086A (it)
DE (1)	DE3245854C2 (it)
FR (1)	FR2518096B1 (it)
GB (1)	GB2111491B (it)
IT (1)	IT1155424B (it)
NZ (1)	NZ202613A (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62267289A (ja) *	1986-04-25	1987-11-19	アボツト　ラボラトリ−ズ	フレカイナイド螢光偏光イムノアツセイにおいて使用するためのトレ−サ−

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2574184B1 (fr) *	1984-11-30	1988-04-22	Centre Nat Rech Scient	Composes fluorescents, derives d'(amino-4 disulfonato-3,6) naphtalimide, leur application aux dosages immunologiques en polarisation de fluorescence
EP0201633A3 (en) *	1984-12-20	1989-02-22	Abbott Laboratories	Substituted anilide compounds and their use
EP0199042A1 (en) *	1985-03-26	1986-10-29	Abbott Laboratories	Procainamide assay, tracers, immunogens and antibodies
DE3682105D1 (de) *	1985-04-01	1991-11-28	Abbott Lab	Probe, tracers, immunogene und antikoerper von ethosuximid.
DE69126915T2 (de) *	1990-05-16	1998-02-19	Abbott Lab	Test für Barbiturate, Tracer, Immunogene, Antikörper und Testsatz dafür
DE4143341C2 (de) *	1991-02-22	1995-05-18	Kernforschungsz Karlsruhe	Verfahren zur Herstellung eines optischen Sensors
US5395933A (en) *	1992-08-07	1995-03-07	Eastman Kodak Company	Carbamazepine hapten analogues
IT1298693B1 (it) *	1996-04-24	2000-01-12	Hoffmann La Roche	Derivati della fluoresceina 4'-metil sostituiti

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5337668A (en) *	1976-04-15	1978-04-06	Technicon Instr	Quantitatively measuring method of medicine from biological liquid sample

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3998943A (en) *	1973-10-02	1976-12-21	Syva Company	Double receptor fluorescent immunoassay

1982
- 1982-11-19 CA CA000416022A patent/CA1248086A/en not_active Expired
- 1982-11-23 GB GB08233403A patent/GB2111491B/en not_active Expired
- 1982-11-25 NZ NZ202613A patent/NZ202613A/en unknown
- 1982-11-25 AU AU90880/82A patent/AU558800B2/en not_active Ceased
- 1982-12-08 FR FR8220591A patent/FR2518096B1/fr not_active Expired
- 1982-12-09 BE BE0/209695A patent/BE895300A/fr not_active IP Right Cessation
- 1982-12-09 JP JP57214749A patent/JPS58113189A/ja active Pending
- 1982-12-10 IT IT24689/82A patent/IT1155424B/it active
- 1982-12-10 DE DE3245854A patent/DE3245854C2/de not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5337668A (en) *	1976-04-15	1978-04-06	Technicon Instr	Quantitatively measuring method of medicine from biological liquid sample

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62267289A (ja) *	1986-04-25	1987-11-19	アボツト　ラボラトリ−ズ	フレカイナイド螢光偏光イムノアツセイにおいて使用するためのトレ−サ−

Also Published As

Publication number	Publication date
AU558800B2 (en)	1987-02-12
DE3245854C2 (de)	1996-11-14
NZ202613A (en)	1985-12-13
IT8224689A1 (it)	1984-06-10
AU9088082A (en)	1983-06-16
GB2111491B (en)	1985-08-21
DE3245854A1 (de)	1983-06-23
CA1248086A (en)	1989-01-03
GB2111491A (en)	1983-07-06
IT8224689A0 (it)	1982-12-10
FR2518096B1 (fr)	1985-12-06
BE895300A (fr)	1983-06-09
IT1155424B (it)	1987-01-28
FR2518096A1 (fr)	1983-06-17

Publication	Publication Date	Title
US4585862A (en)	1986-04-29	Fluorescence polarization immunoassay
US4668640A (en)	1987-05-26	Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4420568A (en)	1983-12-13	Fluorescent polarization immunoassay utilizing substituted triazinylaminofluoresceins
US4476229A (en)	1984-10-09	Substituted carboxyfluoresceins
US4593089A (en)	1986-06-03	Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US5145790A (en)	1992-09-08	Reagents and method for detecting polychlorinated biphenyls
US4510251A (en)	1985-04-09	Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers
US4160016A (en)	1979-07-03	Receptor fluorescent immunoassay
US4161515A (en)	1979-07-17	Double receptor fluorescent immunoassay
US5304645A (en)	1994-04-19	Resorufin derivatives
GB2111476A (en)	1983-07-06	Substituted carboxy- fluoresceins and their use in fluorescence polarization immunoassay
US4255329A (en)	1981-03-10	Double receptor fluorescent immunoassay
US5952187A (en)	1999-09-14	Topiramate immunoassay
US4614823A (en)	1986-09-30	Aminomethylfluorescein derivatives
JPH06211867A (ja)	1994-08-02	蛍光化合物
JPS6214064A (ja)	1987-01-22	置換カルボキシフルオレセイン
JPH08504751A (ja)	1996-05-21	ビオチニル化した化学発光性標識、結合体、測定法及び測定法キット
JPS58113189A (ja)	1983-07-05	螢光偏光免疫分析
US4952691A (en)	1990-08-28	Fluorescence polarization immunoassay
US4275160A (en)	1981-06-23	Imipramine derivatives and poly(amino acid) conjugates
US5066426A (en)	1991-11-19	Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
NZ199629A (en)	1984-11-09	Fluorescent polarisation immunoassay and certain substituted carboxy fluoresceins
JP3899260B2 (ja)	2007-03-28	三環系抗うつ薬誘導体およびイムノアッセイ
CN107003304A (zh)	2017-08-01	用于羟考酮和羟吗啡酮的测定法的缀合物
US5097097A (en)	1992-03-17	Triazinylaminofluoresceins

JPS58113189A - 螢光偏光免疫分析 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=23287816

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (8)

Citations (1)

Family Cites Families (1)

Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents